iData Insights

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H2 2015 Is Released

Press Release   •   Jan 27, 2016 11:56 IST

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H2 2015 Summary Global Markets Direct s, Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Review, H2 2015 , provides an overview of the Vancomycin-Resistant Enterococcus Faecium Infections s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Vancomycin-Resistant Enterococcus Faecium Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vancomycin-Resistant Enterococcus Faecium Infections and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Vancomycin-Resistant Enterococcus Faecium Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Vancomycin-Resistant Enterococcus Faecium Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Vancomycin-Resistant Enterococcus Faecium Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Vancomycin-Resistant Enterococcus Faecium Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Vancomycin-Resistant Enterococcus Faecium Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Vancomycin-Resistant Enterococcus Faecium Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Browsewith TOC @

To Get Sample Copy of Report visit @

Table of Contents

Introduction 9

Global Markets Direct Report Coverage 9

Vancomycin-Resistant Enterococcus faecium Infections Overview 10

Therapeutics Development 11

Pipeline Products for Vancomycin-Resistant Enterococcus faecium Infections - Overview 11

Pipeline Products for Vancomycin-Resistant Enterococcus faecium Infections - Comparative Analysis 12

Vancomycin-Resistant Enterococcus faecium Infections - Therapeutics under Development by Companies 13

Vancomycin-Resistant Enterococcus faecium Infections - Therapeutics under Investigation by Universities/Institutes 15

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Products Glance 16

Clinical Stage Products 16

Early Stage Products 17

Unknown Stage Products 18

Vancomycin-Resistant Enterococcus faecium Infections - Products under Development by Companies 19

Vancomycin-Resistant Enterococcus faecium Infections - Products under Investigation by Universities/Institutes 21

Vancomycin-Resistant Enterococcus faecium Infections - Companies Involved in Therapeutics Development 22

Alchemia Limited 22

Alvogen Korea 23

Aphios Corporation 24

BioSource Pharm, Inc. 25

Cellceutix Corporation 26

Helix BioMedix, Inc. 27

Hsiri Therapeutics, LLC 28

LegoChem Biosciences, Inc 29

Lytix Biopharma AS 30

MGB Biopharma Limited 31

Microbiotix, Inc. 32

MicuRx Pharmaceuticals, Inc. 33

NovaBay Pharmaceuticals, Inc. 34

NovoBiotic Pharmaceuticals, LLC 35

Oragenics, Inc. 36

Sealife PHARMA GMBH 37

Sentinella Pharmaceuticals, Inc. 38

TAXIS Pharmaceuticals, Inc. 39

Wockhardt Limited 40

Vancomycin-Resistant Enterococcus faecium Infections - Therapeutics Assessment 41

Assessment by Monotherapy Products 41

Assessment by Target 42

Assessment by Mechanism of Action 44

Assessment by Route of Administration 46

Assessment by Molecule Type 48

Drug Profiles 50

auriclosene - Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

brilacidin tetrahydrochloride - Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

BSPC-728 - Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

chrysophaentin - Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

closthioamide - Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

Epimerox - Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

HB-1345 - Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

HT-01 - Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

HT-02 - Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

IBN-1 - Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

LCB-010371 - Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

LCB-010699 - Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

LTX-109 - Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

Marinus - Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

MBX-1162 - Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

MGBBP-3 - Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

MRX-I - Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

MRX-IV - Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

MU-1140 - Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

NAI-107 - Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

NAI-603 - Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

SLP-0904 - Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

SLP-0905 - Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

Small Molecule to Inhibit Glycosyltransferase for Bacterial Infection - Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

Small Molecules for MRSA and Vancomycin-Resistant Enterococcus Faecium Infections - Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

Small Molecules to Inhibit FtsZ Protein for MRSA and VRE Infections - Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

Small Molecules to Inhibit Oxacillinase for Gram-Positive Bacterial Infections - Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

SP-2078 - Drug Profile 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

Teixobactin - Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

WCK-4086 - Drug Profile 88

Product Description 88

Mechanism of Action 88

R&D Progress 88

Vancomycin-Resistant Enterococcus faecium Infections - Recent Pipeline Updates 89

Vancomycin-Resistant Enterococcus faecium Infections - Dormant Projects 104

Vancomycin-Resistant Enterococcus faecium Infections - Discontinued Products 105

Vancomycin-Resistant Enterococcus faecium Infections - Product Development Milestones 106

Featured News & Press Releases 106

Feb 25, 2015: MicuRx Initiates U.S. Phase 2 Clinical Trial for Novel Antibiotic MRX-I 106

Aug 26, 2013: Oragenics Collaboration Demonstrates Initial Success in the Second Phase of Lantibiotics Project 106

Feb 12, 2013: Oragenics-Intrexon Collaboration Announces Significant Progress towards Commercial Production of Lead Lantibiotic MU1140 107

Sep 12, 2012: NovaBay Pharma Announces Data from New Study Demonstrating Chemical Impact of N-chlorotaurine And NVC-422 On Bacterial Toxins 107

May 23, 2012: MicuRx Announces Issuance Of US Patent For Next-Generation Antibacterial Agent 108

Apr 23, 2012: MicuRx Completes Phase I Trial for MRX-I 108

Appendix 109

Methodology 109

Coverage 109

Secondary Research 109

Primary Research 109

Expert Panel Validation 109

Contact Us 109

Disclaimer 110

Read More

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

iData Insights

Tel: 1-866-237-2965


AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects